infiltrate and focal vacuolization were found at the dermoepidermal junction. Edema, vessel ectasia, a mild perivascular lymphocytic infiltrate, and mucin deposits were found in the reticular dermis and a lymphocytic infiltrate surrounded hair follicles. At that time anti-SSA antibodies were present, but there were no other abnormalities in the full blood count, renal function, or urinary sediment. There was improvement with topical hydrocortisone, tacrolimus, and photoprotection. One month later, the patient developed fever and lost 1.5 kg in weight, and 3 months later, the rash on the cheeks returned ( Figure 1B ). Repeat biopsies in the malar region were performed in July 2012 but a tissue orientation error prevented interpretation. At that time, a lupus band test from unaffected skin revealed the presence of IgM and IgG granular deposits in the basement membrane. Hydroxychloroquine (HCQ) 400 mg/d was started and the rash improved ( Figure 1C ). Despite HCQ, in December 2012, symmetrical painful violaceous lesions appeared on the tip of the fingers and toes. These resolved with deflazacort 30 mg/d for 1 week, progressively discontinued in the following 3 months. In June 2013, still on HCQ, worsening of the malar rash was documented. In April 2014, the patient reported the onset of pruritic well-defined hyperkeratotic papules initially in the lower limbs, rapidly spreading to the buttocks, upper torso, arms, palms of hands and scalp, resulting in severe alopecia ( Figure 1D ). The complete full blood count, hepatic and renal function tests were within normal ranges. A more extensive profile revealed ANA positivity (1/1280), with an elevated anti-dsDNA, a low C4 and C3. The patient was then treated with daily deflazacort 30 mg, azathioprine (AZA) 50 mg and anti-histaminics, with no improvement. At that time, scabies was suspected and topical treatment with benzyl benzoate was prescribed on two occasions. Several scalp punch biopsies in September 2014 ( Figure 2B ) were reported as compatible with lupus, folliculitis being reported in one of the samples ( Figure 2C ). No periodic acid-Schiff (PAS) positive microorganisms were identified, and there was no immunoglobulin deposition by direct immunofluorescence. The skin condition progressively deteriorated, and both deflazacort and AZA were discontinued. Several discordant histological diagnosis of perforating dermatosis ( Figure 2D ) and psoriasis ( Figure 2E ) ensued. The patient was then treated with oral isotretinoin, whole body psoralen, and ultraviolet-A light therapy (PUVA), 3 times a week (oral 8-Methoxsalen administered before each session with initial, final and total doses of 1.5, 9, and 29.5 J/cm 2 , respectively). These treatments were harmful and stopped after eleven sessions due to the development of generalized, erosive, painful and extremely pruritic disseminated cutaneous lesions with severe alopecia ( Figure  1E ), after which the patient was admitted to our unit in July 2015. Laboratory tests showed leucopenia (3100/μL), neutropenia (1680/μL), ANA positivity (1/640), anti-dsDNA antibodies (277 IU/mL; ELISA reference: <25 IU/mL), complement consumption (C3 = 61 mg/dL [normal range: 90-180 mg/ dL], C4 = 5 mg/dL [normal range: 10-40 mg/dL]), and sustained proteinuria (highest value: 1006 mg/24 h). ELISA tests for anti-Beta-2 Glycoprotein1 and anti-cardiolipin antibodies as well as the lupus anticoagulant assay were negative. The renal biopsy revealed class V membranous glomerulonephritis with granular deposits of immunoglobulins, complement components, and light chains ( Figure S1 ); tissue and serum antiPhospholipase A2 receptor antibody were negative. In view of her skin condition, off-label intravenous immunoglobulin (IVIG) was administered (20 g/d × 5 days) together with HCQ 400 mg/d, and mycophenolate mofetil (MMF) was started at the dose of 500 mg bd and increased weekly by 250 mg bd to a maximum dose of 1 g bd, together with enalapril 5 mg/d. On the 20th day of hospitalization due to the ongoing severity of the skin lesions, the patient was treated with rituximab 
T A B L E 1 Clinical characteristics and sequential histological reports (RTX) 1 g preceded by methylprednisolone 500 mg, on days 1 and 15, in addition to the above-mentioned drugs. The skin rash resolved within 2 weeks of the RTX administration, with residual hypopigmentation ( Figure 1C) ; full hair re-growth was documented at 6 months ( Figure 1D ) with well-being and sustained renal remission at 3 years of follow-up, allowing for successful medication taper (Figure 3) , continuing HCQ and MMF as maintenance treatment.
T A B L E 2 Laboratory results, treatments and outcomes

| DISCUSSION AND CONCLUSIONS
In contrast to lupus nephritis where a renal biopsy has prognostic and therapeutic value with a classification based on well-recognized features, 4 when lupus affects the skin, lesions cannot be distinguished on the grounds of histology alone. 1 Classically, in most cases of SLE, mucin deposition in the dermis is reportedly prominent. Findings may be subtle, with discrete basal cell liquefactive degeneration, papillary dermal edema and perivascular and perifollicular mild chronic inflammatory infiltrate, indistinguishable from subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE). 5, 6 There are, however, histopathological features that are more frequent in some cutaneous subtypes. 7 We envisage the following scenario based on a retrospective clinico-pathological correlation: In April 2012, at disease onset, the patient may have presented with acute cutaneous lupus erythematosus (ACLE), suggested by a scaly localized malar rash. Nevertheless, this was somewhat atypical for ACLE, as the rash was very discrete, there were no systemic features and the lack of scarring after healing was against a diagnosis of DLE. The findings of perivascular and periadnexal lymphocytic infiltration together with mucin deposits, no epidermal change and no thickened basement membrane, were in favor of lupus erythematosus tumidus (LET). The latter corresponded to the morphology of the lesions, characterized by symmetrical erythematous and edematous plaques with a smooth surface and no scales, registered 3 months later, in July 2012. Although HCQ was started, the patient presented 8 months later with a rash on the tip of the fingers and toes suggestive of chilblain lupus. Almost 1 year later, in June 2013, the skin lesions worsened on the face, possibly due to ACLE or LET, as there was no residual scarring. From April 2014, we believe the patient presented with SCLE and SLE, on the basis of papulosquamous lesions that spared the central face and laboratory findings. These lesions were highly pruritic, psoriasiform, and not exclusive to sun-exposed areas. By September 2014, histological findings (orthokeratosis and follicular plugs) were suggestive of scalp DLE leading to intensification of immunosuppression. From then on, a combination of atypical features (the highly pruritic and psoriasiform nature of the lesions), misleading clinical information and refractoriness to therapy distanced the diagnostic path away from SLE, the underlying disease. Several misdiagnosis including scabies, folliculitis, a histological diagnosis of reactive perforating collagenosis vs perforating folliculitis and even psoriasis were evoked at the time, leading to an incorrect treatment choice with PUVA, with severe deleterious consequences. At the time of PUVA treatments, we propose the patient was affected by SCLE, with generalized skin lesions on the entire integument, in addition to SLE. Complete healing with no alopecia and no scarring contradict the diagnosis of scalp DLE. Finally, the hypopigmentation that remained after healing was typical for photosensitive SCLE. In summary, the patient seems to have developed several lupus-specific skin lesions over time, starting at least 2 years before the criteria for the diagnosis of SLE were fulfilled. 8, 9 Different manifestations appeared over time. Initially, ACLE/LET responding favorably to HCQ, immunosuppressants, and sunscreen, and subsequently, SCLE, refractory to therapy. Contrarily to its reportedly favorable prognosis, 10 LET seems to have preceded SLE in this patient. Of note, PUVA treatment is a formal contraindication in patients with photosensitivity. Metabolic disorders and chronic pruritis may be associated with reactive perforating dermatosis. This is a variant of prurigo nodularis, histologically characterized by epidermal perforation 11 for which ultraviolet (UV) light therapy is recommended. 12 But there was no evidence of epidermal perforation and not unexpectedly, in this patient, UV light therapy was equivalent to a major form of photoprovocation, with a deleterious effect, aggravating pre-existing and precipitating new cutaneous lesions, followed by a renal flare. Furthermore, lesions affecting the palms would not be expected to occur in any type of folliculitis. The use of IVIG was justified by the severity of the presentation. The positive long-term response to rituximab with a steroid sparing effect has been previously described, 13, 14 contrasting with the adverse events associated to the prolonged use of systemic steroids in juvenile SLE patients with skin involvement. 15, 16 This report emphasizes the divergence of cutaneous lupus manifestations that may present in a single patient over a period of time and the importance of clinico-pathological correlation for a correct diagnostic and therapeutic approach.
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